Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GEG Tech is a French biotechnology company specializing in the design and production of advanced lentiviral vectors for gene and cell therapy applications. The company’s proprietary Lenti-ONE platform offers a diverse range of vectors, including integrative, non-integrative, and high-capacity systems designed to optimize gene transfer efficiency. Their technology supports a variety of applications such as gene editing via CRISPR/Cas9, cell engineering, and the development of specialized animal models. GEG Tech provides comprehensive services from custom vector design to high-titer production, catering to both academic researchers and pharmaceutical companies. By offering specialized pseudotyping and promoter options, the company enables precise targeting of specific cell types and tissues.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GEG Tech.